688137 近岸蛋白
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.523-3.761-2.5370.5857.088
总资产报酬率 ROA (%)-0.494-3.560-2.4090.5556.374
投入资产回报率 ROIC (%)-0.508-3.644-2.4530.5656.609

边际利润分析
销售毛利率 (%)70.29467.12262.37775.66886.322
营业利润率 (%)-30.719-47.702-41.6134.25139.649
息税前利润/营业总收入 (%)-45.266-67.016-69.126-13.88237.410
净利润/营业总收入 (%)-28.471-53.116-42.6618.38434.293

收益指标分析
经营活动净收益/利润总额(%)54.12256.21271.822159.623102.128
价值变动净收益/利润总额(%)0.000-0.380-5.100276.2973.916
营业外收支净额/利润总额(%)0.1580.7372.099-4.6571.215

偿债能力分析
流动比率 (X)23.22426.83629.12541.30433.351
速动比率 (X)22.33225.92027.99239.60832.147
资产负债率 (%)5.8185.4305.2504.8035.709
带息债务/全部投入资本 (%)0.6630.6571.0080.6360.632
股东权益/带息债务 (%)14,652.20214,767.6529,592.98415,201.72915,250.537
股东权益/负债合计 (%)1,618.7881,741.6631,804.8931,981.8661,651.570
利息保障倍数 (X)3.1223.5352.5970.774-13.720

营运能力分析
应收账款周转天数 (天)152.448149.624179.090218.365146.603
存货周转天数 (天)544.274521.157604.070782.545568.439